Curium
As of the edition of 20 October 2026, Curium runs 14 drugs, 14 of them marketed; it is on route A at 0 targets and on route B at 5 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 14 |
| Total | 14 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Xenon | none listed | 0 |
| Copper oxodotreotide | Ends 2027 (exclusivity) | 1 |
| Sodium iodide | none listed | 0 |
| Gallium citrate | none listed | 0 |
| Indium pentetreotide | none listed | 5 |
| Sodium chromate | none listed | 0 |
| Sodium pertechnetate | none listed | 0 |
| Thallous chloride | none listed | 0 |
| Chromic phosphate | none listed | 0 |
| Indium chloride | none listed | 0 |
| Technetium tc 99m red blood cells | none listed | 0 |
| Technetium mertiatide | none listed | 0 |
| Technetium oxidronate | none listed | 0 |
| Technetium pyrophosphate | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 5 targets.
All 5 rows on route A or B
In the product5 company-target rows on route A or B; 2 are not shown here, and no score is.
See all 5 targets where Curium needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.